<DOC>
	<DOCNO>NCT01598077</DOCNO>
	<brief_summary>This primary purpose study estimate maximum tolerate dose ( MTD ) and/or recommend dose expansion ( RDE ) prefer dose schedule LJM716 give IV infusion adult patient squamous cell carcinoma head neck , esophagus , HER2 overexpressing metastatic breast cancer gastric cancer</brief_summary>
	<brief_title>A Phase I Study LJM716 Squamous Cell Carcinoma Head Neck , HER2+ Breast Cancer Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<criteria>Inclusion criterion : Patients HER2+ breast cancer , HER2+ gastric cancer , squamous cell carcinoma head neck , esophageal squamous cell carcinoma Site disease safely biopsied Exclusion criterion : Patients receive prior antiHER3 antibody treatment Patients impaired cardiac function Brain metastases adequately treat Malignant disease treat study Pregnant nursing ( lactate ) woman Laboratory abnormality specify protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Breast cancer , gastric cancer , squamous cell carcinoma head neck , esophageal squamous cell carcinoma</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Squamous cell carcinoma head neck</keyword>
	<keyword>Esophageal squamous cell carcinoma</keyword>
</DOC>